Societe Generale’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Societe Generale’s Portfolio OXFD Stock Details OXFD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$114K	Buy	+12,717	New	+$125K	﹤0.01%	2330

Other funds holding OXFD

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Societe Generale's OXFD Position: Q2 2016 in Review

Societe Generale opened a new position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q2 2016: 12,717 shares worth $114K. The stake represents ﹤0.01% of the portfolio and ranks #2330 among its holdings.

56 funds tracked by Wall St. Rank hold OXFD as of Q2 2016.

Societe Generale held 12,717 shares of Oxford Immunotec Global PLC Ordinary Shares worth $114K as of Q2 2016.
Oxford Immunotec Global PLC Ordinary Shares was a new Societe Generale position in Q2 2016.
Oxford Immunotec Global PLC Ordinary Shares made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2330 holding.
56 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.